CTA1-DD is an effective adjuvant for targeting anti-chlamydial immunity to the murine genital mucosa

被引：35

作者：

Cunningham, Kelly A. ^{[1
]}

Carey, Alison J. ^{[1
]}

Lycke, Nils ^{[2
]}

Timms, Peter ^{[1
]}

Beagley, Kenneth W. ^{[1
]}

机构：

[1] Queensland Univ Technol, Inst Hlth & Biomed Innovat, Brisbane, Qld 4059, Australia

[2] Univ Gothenburg, Dept Microbiol & Immunol, Mucosal Immunol & Vaccine Res Ctr, Inst Biomed, S-40530 Gothenburg, Sweden

来源：

JOURNAL OF REPRODUCTIVE IMMUNOLOGY | 2009年 / 81卷 / 01期

关键词：

Chlamydia; CTA1-DD; Mucosal adjuvant; OUTER-MEMBRANE PROTEIN; INFLUENZA VACCINE; PROTECTIVE IMMUNITY; IMMUNIZATION; INFECTION; TRACT; CHALLENGE; INDUCTION; MICE; VP6;

D O I：

10.1016/j.jri.2009.04.002

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

071005 [微生物学]; 100108 [医学免疫学];

摘要：

Chlamydia trachomatis is a significant human pathogen with potentially severe disease sequelae in the genital tract, including infertility. A successful vaccine will need to effectively target immunity to the genital mucosa. Intranasal immunisation with cholera toxin (CT) can target immunity to the genital tract, but has the potential to cause neurological side effects. CTA1-DD is a non-toxic potent mucosal adjuvant which combines the enzymatic properties of CT, with a B cell targeting moiety. Here, we demonstrate that intranasal immunisation with CTA1-DD and chlamydial Major Outer Membrane Protein (MOMP) results in the induction of neutralising systemic and mucosal antibodies. and reduces the level of chlamydial shedding following intravaginal challenge with Chlamydia muridarum. Thus, CTA1-DD is an effective adjuvant for vaccine development against Chlamydia trachomatis, and possibly also a range of other genital pathogens. (C) 2009 Elsevier Ireland Ltd. All rights reserved.

引用

页码：34 / 38

页数：5

共 22 条

[1]

Agren LC, 1997, J IMMUNOL, V158, P3936

[2]

The nontoxic CTA1-DD adjuvant enhances protective immunity against Helicobacter pylori infection following mucosal immunization [J].